+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-sequencing, NGS Data Analysis), By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 180 Pages
  • June 2023
  • Region: Global
  • Grand View Research
  • ID: 5415632
Description Jump to:
The global clinical oncology next generation sequencing market size is expected to reach USD 1.16 billion by 2030, according to this report. The market is expected to expand at a CAGR of 15.7% from 2023 to 2030. The clinical oncology next generation sequencing (NGS) market is in high demand. It is projected to expand at an increasing rate throughout the forecast period owing to the rising healthcare expenditure triggering the development of effective personalized medicine & therapeutic procedures for cancer and increasing adoption of NGS.

The increasing healthcare expenses and the launch of effective cancer treatments are expected to fuel market growth over the forecast period. A study published by the JAMA network in February 2023 estimated that the cost of cancer treatment can reach up to USD 25 trillion globally over the 30 years from 2020-2030. The comparative contribution of treatment expenses to the total economic expense of cancers was found to be more significant in high-income nations than in low-income nations. Moreover, various treatment techniques are being developed and utilized to diagnose and treat cancer. According to the study published by Wiley in January 2023, technological advances that are being used to develop new diagnostic techniques include image reconstruction software, imaging devices, hardware, biomarkers, and artificial intelligence algorithms, thereby delivering a reliable analysis and diagnosis of the tumor.

Furthermore, the growth of the clinical oncology next-generation sequencing market during the forecast period is propelled by the rise in the adoption of NGS over single gene testing. Many studies demonstrated that NGS is cost-effective and efficient over single gene testing. For instance, a study published by JCO Precision Oncology in March 2023 concluded that the adoption of NGS in Spanish reference centers to diagnose patients with NSCLC could be a cost-effective strategy over single gene testing. In addition, the study given by the National Library of Medicine in January 2023, suggests that the current NGS over sequential single-gene testing can slightly reduce annual costs. However, embracing NSG over SSG testing can decrease the average turnaround time, facilitating quicker identification of genomic alterations and early initiating therapy for small cell lung cancer patients in Japan. These factors are expected to drive the market over the forecast period.

Clinical Oncology Next Generation Sequencing Market Report Highlights

  • In the workflow segment, NGS sequencing dominated the market with a revenue share of 56.0% in 2022, owing to technological advancements and the rising number of cancer sequencing projects
  • By technology, the targeted sequencing and resequencing accounted for the largest revenue share of 72.7% in the clinical oncology NGS market in 2022. This can be attributed to the growing clinical utility of targeted panels and their efficiency in detecting cancer tumors
  • By application, the screening segment held the highest share of 80.1% in 2022. The segment's dominance is due to the increasing prevalence of cancer worldwide
  • By end-use, the laboratories segment accounted for the largest share of 64.1% in the clinical oncology NGS market in 2022. This can be attributed to the rising number of research and development activities
  • North America held the largest market share of 48.68% in 2022. The dominance of the region is due to the presence of prominent international players in the market and rising investments from public and private organizations in life science research & solutions developments in the region

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Decrease in costs for genetic sequencing
3.2.1.2. Advancements in the field of personalized medicine
3.2.1.3. Rise in competition amongst prominent market entities
3.2.1.4. Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
3.2.1.5. Rise in prevalence of cancer
3.2.1.6. Growing adoption of NGS over single gene testing
3.2.2. Market Restraint Analysis
3.2.2.1. Lack of computational efficiency for data management
3.2.2.2. Non-value based NGS reimbursement policy
3.3. Industry Analysis Tools
3.3.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.3.2. Porter's Five Forces Analysis
3.3.3. Penetration and Growth Prospect Mapping, 2022
3.4. COVID-19 Impact Analysis
Chapter 4. Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis
4.1. Clinical Oncology NGS Market: Technology Movement Analysis
4.2. Clinical Oncology NGS Market Estimates & Forecast, By Technology (USD Million)
4.3. Whole Genome Sequencing
4.3.1. Whole Genome Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
4.4. Whole Exome Sequencing
4.4.1. Whole Exome Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
4.5. Targeted Sequencing & Resequencing
4.5.1. Targeted Sequencing & Resequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
Chapter 5. Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis
5.1. Clinical Oncology NGS Market: Workflow Movement Analysis
5.2. Clinical Oncology NGS Market Estimates & Forecast, By Workflow (USD Million)
5.3. NGS Pre-Sequencing
5.3.1. NGS Pre-Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
5.4. NGS Sequencing
5.4.1. NGS Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
5.5. NGS Data Analysis
5.5.1. NGS Data Analysis For Clinical Oncology Market, 2018 - 2030 (USD Million)
Chapter 6. Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis
6.1. Clinical Oncology NGS Market: Application Movement Analysis
6.2. Clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
6.3. Screening
6.3.1. Screening Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
6.3.2. Sporadic Cancer
6.3.2.1. Sporadic cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
6.3.3. Inherited cancer
6.3.3.1. Inherited cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
6.4. Companion Diagnostics
6.4.1. Companion diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
6.5. Other Diagnostics
6.5.1. Other diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
Chapter 7. Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis
7.1. Clinical Oncology NGS Market: End Use Movement Analysis
7.2. Clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
7.3. Hospitals
7.3.1. Hospitals Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
7.4. Clinics
7.4.1. Clinics clinical oncology NGS market, 2018 - 2030 (USD Million)
7.5. Laboratories
7.5.1. Laboratories clinical oncology NGS market, 2018 - 2030 (USD Million)
Chapter 8. Clinical Oncology Next Generation Sequencing Market Regional Business Analysis
8.1. Clinical Oncology Next Generation Sequencing Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. North America Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Competitive Scenario
8.2.2.3. Regulatory Framework
8.2.2.4. U.S. Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Competitive Scenario
8.2.3.3. Regulatory Framework
8.2.3.4. Canada Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.3.2. UK
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. UK Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Germany Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. France Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Regulatory Framework
8.3.5.4. Italy Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Regulatory Framework
8.3.6.4. Spain Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Competitive Scenario
8.3.7.3. Regulatory Framework
8.3.7.4. Denmark Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Competitive Scenario
8.3.8.3. Regulatory Framework
8.3.8.4. Sweden Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Competitive Scenario
8.3.9.3. Regulatory Framework
8.3.9.4. Norway Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. Japan Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. China Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. India Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.4.5. Australia
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Australia Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.4.6. Thailand
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Thailand Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.4.7. South Korea
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. South Korea Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Brazil Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Mexico Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. Argentina Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.6. MEA
8.6.1. MEA Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. South Africa Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Saudi Arabia Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. UAE Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Kuwait Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.3. Company Profiles/Listing
9.3.1. Illumina, Inc.
9.3.1.1. Overview
9.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.1.3. Product Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Thermo Fisher Scientific Inc.
9.3.2.1. Overview
9.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.2.3. Product Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. F. Hoffmann-La Roche Ltd
9.3.3.1. Overview
9.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.3.3. Product Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Agilent Technologies, Inc.
9.3.4.1. Overview
9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Myriad Genetics, Inc.
9.3.5.1. Overview
9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Beijing Genomics Institute (BGI)
9.3.6.1. Overview
9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. QIAGEN
9.3.7.1. Overview
9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Perkin Elmer, Inc.
9.3.8.1. Overview
9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. PacBio
9.3.9.1. Overview
9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.9.3. Product Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Partek Incorporated
9.3.10.1. Overview
9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.10.3. Product Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Foundation Medicine Inc.
9.3.11.1. Overview
9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.11.3. Product Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. Oxford Nanopore Technologies
9.3.12.1. Overview
9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.12.3. Product Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. Paradigm Diagnostics, Inc.
9.3.13.1. Overview
9.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.13.3. Product Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. Caris Life Sciences
9.3.14.1. Overview
9.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.14.3. Product Benchmarking
9.3.14.4. Strategic Initiatives
9.3.15. Eurofins Scientific
9.3.15.1. Overview
9.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.15.3. Product Benchmarking
9.3.15.4. Strategic Initiatives
9.3.16. PerkinElmer, Inc.
9.3.16.1. Overview
9.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.16.3. Product Benchmarking
9.3.16.4. Strategic Initiatives
List of Tables
Table 1: Cancer Incidence and Mortality, By Region, 2018
Table 2: Genes associated with breast and ovarian cancer that can be sequenced by NGS panel
Table 3: FDA-Approved NGS Tumor-Profiling Tests for Companion Diagnostics
Table 4: Gene-panels used in clinics for Hereditary Breast/Ovarian Cancer (HBOC)
Table 5: North America clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 6: North America clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 7: North America clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 8: North America clinical oncology NGS screening market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 9: North America clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 10: U.S. clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 11: U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 12: U.S. clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 13: U.S. clinical oncology NGS screening market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 14: U.S. clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 15: Canada clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 16: Canada clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 17: Canada clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 18: Canada clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 19: Europe clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 20: Europe clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 21: Europe clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 22: Europe clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 23: Germany clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 24: Germany clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 25: Germany clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 26: Germany clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 27: UK clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 28: UK clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 29: UK clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 30: UK clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 31: France clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 32: France clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 33: France clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 34: France clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 35: Italy clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 36: Italy clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 37: Italy clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 38: Italy clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 39: Spain clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 40: Spain clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 41: Spain clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 42: Spain clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 43: Denmark clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 44: Denmark clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 45: Denmark clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 46: Denmark clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 47: Sweden clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 48: Sweden clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 49: Sweden clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 50: Sweden clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 51: Norway clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 52: Norway clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 53: Norway clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 54: Norway clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 55: Asia Pacific clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 56: Asia Pacific clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 57: Asia Pacific clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 58: Asia Pacific clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 59: Japan clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 60: Japan clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 61: Japan clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 62: Japan clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 63: China clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 64: China clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 65: China clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 66: China clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 67: India clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 68: India clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 69: India clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 70: India clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 71: South Korea clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 72: South Korea clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 73: South Korea clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 74: South Korea clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 75: Australia clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 76: Australia clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 77: Australia clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 78: Australia clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 79: Thailand clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 80: Thailand clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 81: Thailand clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 82: Thailand clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 83: Latin America clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 84: Latin America clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 85: Latin America clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 86: Latin America clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 87: Brazil clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 88: Brazil clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 89: Brazil clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 90: Brazil clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 91: Mexico clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 92: Mexico clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 93: Mexico clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 94: Mexico clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 95: Argentina clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 96: Argentina clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 97: Argentina clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 98: Argentina clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 99: Middle East & Africa clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 100: Middle East & Africa clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 101: Middle East & Africa clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 102: Middle East & Africa clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 103: South Africa clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 104: South Africa clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 105: South Africa clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 106: South Africa clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 107: Saudi Arabia clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 108: Saudi Arabia clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 109: Saudi Arabia clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 110: Saudi Arabia clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 111: UAE clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 112: UAE clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 113: UAE clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 114: UAE clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
Table 115: Kuwait clinical oncology NGS market estimates & forecasts, by technology, 2018-2030 (USD Million)
Table 116: Kuwait clinical oncology NGS market estimates & forecasts, by workflow, 2018-2030 (USD Million)
Table 117: Kuwait clinical oncology NGS market estimates & forecasts, by application, 2018-2030 (USD Million)
Table 118: Kuwait clinical oncology NGS market estimates & forecasts, by end use, 2018-2030 (USD Million)
List of Figures
Fig. 1: Market snapshot
Fig. 2: Market research process
Fig. 3: Information procurement
Fig. 4: Primary research pattern
Fig. 5: Market research approaches
Fig. 6: Value chain based sizing & forecasting
Fig. 7: QFD modelling for market share assessment
Fig. 8: Market trends & outlook
Fig. 9: Market segmentation & scope
Fig. 10: Penetration & growth prospect mapping for application, 2022
Fig. 11: Penetration & growth prospect mapping for prominent industry players, 2022
Fig. 12: Market driver relevance analysis (Current & future impact)
Fig. 13: Cost per raw mega base (Mb) of DNA sequence (USD)
Fig. 14: Cost per genome
Fig. 15: Expected rise in expenditure for cancer treatment (USD Billion)
Fig. 16: Number of new cancer cases in the World, 2022
Fig. 17: Market restraint relevance analysis (Current & future impact)
Fig. 18: SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 19: Porter’s Five Forces Analysis
Fig. 20: Strategy framework
Fig. 21: Participant categorization
Fig. 22: Clinical oncology NGS market: Technology outlook key takeaways
Fig. 23: Clinical oncology NGS market: Technology movement analysis
Fig. 24: Whole genome sequencing for clinical oncology market, 2018-2030 (USD Million)
Fig. 25: Whole exome sequencing for clinical oncology market, 2018-2030 (USD Million)
Fig. 26: Targeted sequencing and resequencing for clinical oncology market, 2018-2030 (USD Million)
Fig. 27: Clinical oncology NGS market: Workflow outlook key takeaways
Fig. 28: Clinical oncology NGS market: Workflow movement analysis
Fig. 29: NGS Pre-sequencing for clinical oncology market, 2018-2030 (USD Million)
Fig. 30: NGS Sequencing for clinical oncology market, 2018-2030 (USD Million)
Fig. 31: NGS Data analysis for clinical oncology market, 2018-2030 (USD Million)
Fig. 32: Clinical oncology NGS market: Application outlook key takeaways
Fig. 33: Clinical oncology NGS market: Application movement analysis
Fig. 34: Screening clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 35: Sporadic cancer screening clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 36: Lifetime cancer risks for common cancers
Fig. 37: Inherited cancer screening clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 38: Companion diagnostics clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 39: Other diagnostics clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 40: Clinical oncology NGS market: End use outlook key takeaways
Fig. 41: Clinical oncology NGS market: End use movement analysis
Fig. 42: Hospitals clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 43: Clinics clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 44: Laboratories clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 45: Regional market place: Key takeaway
Fig. 46: Clinical oncology NGS market: Regional outlook, 2018 & 2025
Fig. 47: North America clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 48: U.S. clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 49: Canada clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 50: Europe clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 51: Germany clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 52: UK clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 53: France clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 54: Italy clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 55: Spain clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 56: Denmark clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 57: Sweden clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 58: Norway clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 59: Asia Pacific clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 60: Japan clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 61: China clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 62: Thailand clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 63: India clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 64: South Korea clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 65: Australia clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 66: Latin America clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 67: Brazil clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 68: Mexico clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 69: Argentina clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 70: Middle East & Africa clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 71: South Africa clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 72: Saudi Arabia clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 73: UAE clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 74: Kuwait clinical oncology NGS market, 2018-2030 (USD Million)
Fig. 75: Key companies profiled

Companies Mentioned

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Myriad Genetics, Inc.
  • Beijing Genomics Institute (BGI)
  • QIAGEN
  • Perkin Elmer, Inc.
  • PacBio
  • Partek Incorporated
  • Foundation Medicine Inc.
  • Oxford Nanopore Technologies
  • Paradigm Diagnostics, Inc.
  • Caris Life Sciences
  • Eurofins Scientific
  • PerkinElmer, Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedJune 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 370 Million
Forecasted Market Value ( USD ) by 2030 $ 1160 Million
Compound Annual Growth Rate15.7%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Oncology NGS Market by Product Type, Cancer Type, Application, End User - Global Forecast to 2030 - Product Image

Oncology NGS Market by Product Type, Cancer Type, Application, End User - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Clinical Oncology Next Generation Sequencing - Global Strategic Business Report - Product Image

Clinical Oncology Next Generation Sequencing - Global Strategic Business Report

  • Report
  • 462 Pages
  • Global
From
Clinical Oncology Next-Generation Sequencing Market by Technology, by Workflow, by Application, by End-user, and by Region - Product Image

Clinical Oncology Next-Generation Sequencing Market by Technology, by Workflow, by Application, by End-user, and by Region

  • Report
  • 200 Pages
  • Global
From
NGS Library Preparation Automation Market by Product Type, Application, Automation, End User - Global Forecast to 2030 - Product Image

NGS Library Preparation Automation Market by Product Type, Application, Automation, End User - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
NGS-based RNA-sequencing Market Size, Share & Trends Analysis Report by Product & Service (Consumables, Instruments, Services), Workflow (Pre-sequencing, Sequencing, Data Analysis), Application, End Use, Region, with Growth Forecasts, 2025-2030 - Product Image

NGS-based RNA-sequencing Market Size, Share & Trends Analysis Report by Product & Service (Consumables, Instruments, Services), Workflow (Pre-sequencing, Sequencing, Data Analysis), Application, End Use, Region, with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.